Partner study description

Randomized trial to assess the safety, tolerability and efficacy of arterolane-piperaquine, arterolane-piperaquine+mefloquine and artemether-lumefantrine. Number of subjects 219. We obtain parasite clearance half lives and travel surveys.

Publications

• Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial
  Wamae et al
  Wellcome Open Research, 2024; 7 95
  10.12688/wellcomeopenres.17736.2
• Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial
  Hamaluba et al
  The Lancet Infectious Diseases, 2021; 21(10) 1395-1406
  10.1016/S1473-3099(20)30929-4